Related Experiment Videos
Autologous bone marrow transplantation in pediatric solid tumors
Pediatric Hematology and Oncology
|January 1, 1990
Summary
High-dose chemotherapy and autologous bone marrow transplant show promise for relapsed pediatric solid tumors. However, long-term survival benefits over conventional treatments remain limited, necessitating improved induction regimens.
Area of Science:
- Pediatric Oncology
- Hematology
- Stem Cell Transplantation
Background:
- Massive chemotherapy and autologous bone marrow transplantation (BMT) have been increasingly used for pediatric solid tumors in the last 5 years.
- Tumors treated include neuroblastoma, Ewing's sarcoma, rhabdomyosarcoma, Wilms' tumor, germ cell tumors, osteosarcoma, and retinoblastoma.
Purpose of the Study:
- To evaluate the effectiveness of high-dose chemotherapy and autologous BMT in treating pediatric solid tumors.
- To identify areas for improvement in current treatment protocols.
Main Methods:
- Review of recent studies on high-dose chemotherapy and autologous BMT for pediatric solid tumors.
- Analysis of treatment outcomes, focusing on disease course modification and long-term survival.
Main Results:
- While the disease course can be significantly altered in most cases, long-term survival improvements over conventional treatments are not substantial.
- This approach shows promise for relapsed patients, potentially offering the only curative option.
Conclusions:
- High-dose chemotherapy and autologous BMT are valuable for specific pediatric solid tumors, particularly in relapsed settings.
- There is a critical need for the development of novel and more effective induction regimens to improve long-term survival outcomes.